Stories

Public perceptions of e-cigarettes' risks have shifted due to factors like the EVALI scare. Although e-cigarettes were initially seen as less harmful than cigarettes, negative views have increased. A study analyzed data from a clinical trial of smokers using e-cigarettes, finding that perceptions of e-cigarette risk rose after EVALI. Even though e-cigarettes are generally considered less harmful, EVALI led to a temporary increase in perceived risk. The study suggests monitoring smokers' perceptions of e-cigarettes to guide future policies. Correcting misperceptions is vital to encourage smokers to transition to less harmful options. Recommendations include FDA-approved aids for smoking cessation over e-cigarettes.

Around 41 million people globally live with HIV, with smoking rates among this group being significantly higher than national averages. In countries like Australia, Austria, Germany, and Italy, up to half of people with HIV smoke. The National Cancer Institute notes that smoking cessation is crucial for those with HIV, as it can impact life expectancy and increase the risk of smoking-related diseases. Interventions to quit smoking should be integrated into HIV care services, as seen in countries like Switzerland and the United States. Safer nicotine products may play a vital role in helping people with HIV quit smoking and improve their overall health outcomes.

The FDA on Tuesday authorized the sale of fruit-flavored electronic cigarettes for the first time, clearing four products from Los Angeles-based vaping company Glas Inc. for adult use in the U.S. The authorized products — marketed under the names Gold, Sapphire, Classic Menthol, and Fresh Menthol — are e-liquid pods containing 50mg/ml of tobacco-derived nicotine, according to the FDA. Gold and Sapphire are mango and blueberry flavors, respectively, according to NBC News. Until Tuesday's action, every federally authorized vaping product had been either tobacco- or menthol-flavored.

Europe permits limited recreational cannabis commerce for research purposes through pilot trials, allowing local consumers, producers, and retailers to participate. Switzerland and the Netherlands have successful pilot projects, while Germany recently passed the CanG measure legalizing personal cannabis use and cultivation. Despite interest, Germany has not yet approved any pilot trial applications. Research aims to evaluate economic, health-related, and social impacts, potentially influencing broader legalization in Germany and the EU. Success in Switzerland and the Netherlands indicates Germany could also effectively implement pilot trials.

Growing attention is being given to the possible connection between GLP-1 drugs such as Ozempic and smoking cessation. Discussion among medical professionals suggests that appetite- and craving-reducing treatments could potentially support people trying to move away from cigarettes and other nicotine products. According to some clinicians, this overlap may open new opportunities for combining harm reduction strategies with broader metabolic and cardiovascular care. At the same time, reluctance within parts of the pharmaceutical and medical sectors continues to limit wider exploration of nicotine harm reduction. The debate reflects a broader shift in how addiction, nicotine use and long-term public health challenges are increasingly being understood.

A smoke-free world by 2040 is increasingly being viewed as an achievable public health goal rather than a distant ambition. New international research suggests that wider use of smoke-free nicotine products, including vapes and oral pouches, could significantly accelerate the decline in smoking rates. Countries such as Sweden, New Zealand and Japan are frequently cited as examples where access to reduced-risk alternatives has coincided with rapid falls in cigarette use. Critics of current policies argue that treating all nicotine products the same risks slowing progress and discouraging smokers from switching. The debate ultimately centres on whether harm reduction should play a central role in future tobacco control strategies.

The influence of private funding on global public health policy is becoming an increasingly debated issue. Analysis highlights how large-scale philanthropic investment can shape not only funding priorities but also the direction of international health strategies. In the case of Michael Bloomberg, billions of dollars have been channelled into tobacco control initiatives through a network of interconnected organisations. This structure is argued to amplify a single policy perspective across multiple institutions, including programmes linked to the World Health Organization. Critics suggest that such influence may limit debate around harm reduction approaches and alternative nicotine products. The discussion raises broader questions about transparency, accountability and the role of private actors in shaping global health agendas.

The influence of private funding on global public health policy is becoming an increasingly debated issue. Analysis highlights how large-scale philanthropic investment can shape not only funding priorities but also the direction of international health strategies. In the case of Michael Bloomberg, billions of dollars have been channelled into tobacco control initiatives through a network of interconnected organisations. This structure is argued to amplify a single policy perspective across multiple institutions, including programmes linked to the World Health Organization. Critics suggest that such influence may limit debate around harm reduction approaches and alternative nicotine products. The discussion raises broader questions about transparency, accountability and the role of private actors in shaping global health agendas.

Harm reduction is widely used across public policy, yet it remains underutilised in tobacco regulation. In South Africa, the approach is already applied in areas such as road safety, public health and environmental policy to manage risk rather than eliminate behaviour. The same principle could be extended to smoking, where reducing harm may be more effective than relying solely on abstinence-based strategies. Evidence suggests that policies recognising behavioural realities tend to achieve better public health outcomes. At the same time, current debates often fail to distinguish between different nicotine products and their relative risks. A more balanced, risk-proportionate approach could improve outcomes by aligning regulation with scientific evidence and real-world behaviour.

Concerns are growing in the UK over the potential impact of a new vape tax set to take effect in October 2026. A survey of over 2,600 adults suggests strong opposition, with many users fearing that rising costs could make vaping less affordable. The planned duty is expected to add around £2.64 to a standard 10ml bottle of e-liquid, significantly increasing regular expenses for users. Many respondents indicated that higher prices could make it harder to stay smoke-free, with some even considering a return to cigarettes. The findings highlight concerns that price-driven policies may unintentionally undermine smoking cessation efforts. They also raise broader questions about whether taxation is being used primarily as a public health tool or a source of revenue.